



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

p16INK4a Recombinant Monoclonal Antibody [BC42]

Mouse Recombinant Monoclonal

Purified RefSeq ID NP_000068.1
Catalog No. A700-292CF Uniprot ID P42771
Lot No. 1

APPLICATIONS	WB, IHC, ICC, Flow Cyt
SPECIES REACTIVITY	Human
AMOUNT	100 µl
CONCENTRATION	1000 µg/ml
STORAGE/SHELF LIFE	2 – 8°C / 1 year from date of receipt
PHYSICAL STATE	Liquid
BUFFER	Borate Buffered Saline (BBS) pH 8.2 with 0.09% Sodium Azide, BSA-Free
ISOTYPE	IgG1
CLONE #	BC42
ORIGIN	USA
PRODUCTION PROCEDURES	Recombinant antibody was manufactured using variable regions (VH and VL) derived from the hybridoma.

Recombinant antibody was purified from cell culture supernatant.

Immunogen was a recombinant protein corresponding to human p16 INK4A.

APPLICATIONS Centrifuge tube to remove product from lid. Optimal working dilutions should be determined experimentally by the investigator. Prepare working dilution immediately before use.

A700-292CF is the carrier-free formulation of BC42 . This product is optimized for conjugation with enzymes, fluorochromes, biotin, radioisotopes, oligonucleotides, microspheres, and other reagents. The optimal experimental concentration of the antibody post-conjugation must be determined by the investigator.

This document certifies that this product has met all of the quality control standards defined by Bethyl Laboratories, Inc.
Michael Spencer, PhD Date: September 28, 2023